Every year, World Toilet Day is observed to raise awareness about the global sanitation crisis and encourage action to solve it. The goal set by the United Nation is to achieve safe toilets for all by 2023, as a part of their Sustainable Development Goals.

The UN also states that 3.5 billion people live without proper sanitation and many children also lose their lives due to poor sanitation and unsafe water. This is why World Toilet Day is observed to raise awareness on this issue.

Theme

This year, the theme for World Toilet Day 2024 is "Toilets - A Place for Peace'. This focuses on the growing threat to sanitation that is caused by conflict, climate change, disaster and neglect. When there is a threat to using toilets, it can lead to many health risks.

Not using toilets for too long may lead to Urinary Tract Infection or UTI. For many who do not have access to clean toilets do not drink enough liquid or hold pee for too long. Doctors suggest that holding in pee for too long can cause bacteria to multiply and lead to UTI. By not drinking enough water, your bladder fails to tell the body to pee often, and can cause the bacteria to spread through the urinary tract, which can lead to infection.

Symptoms of UTI:

• Burning or stinging feeling while urinating
• Pain in pelvis or lower abdomen
• Constant urge to empty the bladder
• Strong or foul smelling urine
• Consistently dark urine
• Blood in urine

Holding in pee for too long can also cause your bladder to stretch, making it difficult or even impossible for the bladder to contract and release pee normally. It can also damage your pelvic floor muscles or could lead to kidney stones.

World Toilet Day History And Significance

To prevent such conditions, it is important that everyone has access to clean and safe toilets. In terms of history, the day was established in 2001, by the World Toilet Organization (WTO), which was founded by Jack Sim. However, it was officially recognised by the UN in 2013. The Government of Singapore worked with WTO to create the first UN resolution called Sanitation for All.

India too promotes safe and hygiene toilet through its Swachh Bharat Yojna.

More than 11,000 bottles of the blood pressure medication Chlorthalidone, manufactured in India, have been recalled in the United States, according to the Food and Drug Administration (FDA). This is the second India-made blood pressure drug to be recalled in over a month.

Mumbai-based manufacturer Inventia Healthcare Limited recalled the prescription-only Chlorthalidone Tablets USP, 25 mg on June 5 due to "failed dissolution specifications." This means that the tablets may not break down correctly in the body. The drug is sold under several brand names, including Thalitone and Hygroton, and is distributed in America by New Jersey-based Rising Pharma Holdings.

What Is Chlorthalidone Used For?

Also read: Robert F. Kennedy Jr. Launches Reforms To Speed Up Early Drug Research In US

Chlorthalidone is a diuretic, or "water pill," prescribed to treat high blood pressure and fluid retention associated with conditions such as congestive heart failure, kidney disease, and liver disease.

It works by helping the kidneys eliminate excess water and salt through urine.

The FDA has not yet classified the recall or detailed the potential health consequences for patients.

What Does Dissolution Of A Drug Mean?

Dissolution refers to the process by which a tablet breaks down and releases its active ingredient into the body after it is taken.

A dissolution failure means that, during regulatory testing, the tablets did not dissolve as required. As a result, the active ingredient may not be released properly, potentially reducing the amount of medicine that reaches the bloodstream and works as intended, according to Cardiovascular Business..

Dissolution problems can arise from several factors, including poor formulation design, manufacturing process issues, low-quality raw materials, or stability issues that affect the product over time.

Which Medication Has Been Recalled?

Also read: US FDA Panel Recommends First-Ever mRNA Flu Shot For Older Adults: All About The Moderna Vaccine

According to the FDA, 11,460 bottles of Chlorthalidone are included in the recall and carry an expiration date of April 2027.

The recall affects:

• 100-tablet bottles marked with batch RISA24001
• 1,000-tablet bottles marked with batch RISB24002

Second BP Drug Recall

Read More: 4 Indian States Roll Out IV Iron Therapy To Curb Anemia In Pregnant Women: How It Works

The recall follows another FDA recall announced on May 5 involving Amlodipine and Olmesartan Medoxomil Tablets (5 mg/40 mg), another prescription blood pressure medication.

A total of 15,696 bottles were recalled due to "failed dissolution specifications: Olmesartan Medoxomil content below specifications."

The medication was also manufactured by Alkem Laboratories Ltd. in India and distributed by Ascend Laboratories, LLC, Parsippany, New Jersey. The recalled bottles carry an expiration date of October 31, 2027.

Both recalls were issued nationwide.

Previous Large-Scale Blood Pressure Drug Recall

The latest recall follows a separate large-scale blood pressure medication recall in October, when manufacturers recalled more than 500,000 bottles of Prazosin Hydrochloride due to contamination concerns.

That recall involved potential contamination with unsafe levels of a cancer-causing chemical, prompting the manufacturer to advise patients to consult their physicians or pharmacists.

The US Department of Health and Human Services (HHS), led by Robert F. Kennedy Jr., today launched a department-wide effort aimed at restoring American leadership in clinical trials and drug testing.

“Today, HHS launched a historic department-wide effort to strengthen America’s clinical research enterprise and ensure the next generation of medical breakthroughs is developed right here in the United States. Under President Trump’s leadership, we are accelerating innovation, expanding research capacity, and ensuring lifesaving discoveries are made in America,” Kennedy wrote in a post on social media platform X.

The Food and Drug Administration (FDA)-led pilot initiative, called Operation TrialBlazer comes at a time when China is gaining ground in the global biotechnology race.

Writing in a Fox News op-ed, Kennedy said, “America should continue to lead the world in clinical research and medical innovation. Instead, we are losing ground.”

He cited a recent study showing that China now conducts more early-stage clinical trials than the United States.

In 2025, Chinese companies accounted for nearly half of global pharmaceutical licensing deal activity. “Those trends should concern every American,” Kennedy said, stressing that “the future of medicine should be built in America.”

The coordinated department-wide effort aims to accelerate the development of lifesaving treatments in the United States and ensure that patients have access to some of the most innovative therapies in the world.

The initiative brings together multiple HHS divisions, including the Food and Drug Administration (FDA), the National Institutes of Health (NIH), the Advanced Research Projects Agency for Health (ARPA-H), and the Office of the Inspector General (OIG).

The effort aims to:

• Eliminate unnecessary delays
• Reduce redundant requirements
• Address regulatory ambiguity that can slow and disincentivize U.S.-based development
• Encourage the broader biomedical research ecosystem to do the same
• Foster a clinical research economy that delivers timely, safe, and effective medical products to support a healthy America

What Is Operation TrialBlazer?

According to the FDA, the initiative will help shorten development timelines by six to 12 months through a series of measures, including pairing drug developers with qualified academic centers and contract research organizations to prepare first-in-human trial applications.

The FDA has also issued draft guidance clarifying that, in many cases, one high-quality late-stage clinical trial with confirmatory evidence will generally be sufficient to provide substantial evidence of effectiveness in support of a drug approval.

Other Programs To Accelerate Drug Research In The US

Read More: Powassan Virus: Deadly Tick-Borne Disease Spreading Across The US; Here's What You Need To Know

In addition to FDA's Operation TrialBlazer, the HHS has proposed initiatives by other divisions such as:

• NIH: Expanding support for well-powered clinical trials while advancing the use of AI, human cell-based models, real-world data, and practical trial tools to speed up therapy development without compromising scientific rigor.
• NCATS: Building on work that led to the first fully personalized CRISPR-based gene-editing treatment to accelerate therapies for rare diseases.
• National Cancer Institute (NCI): Working with cancer centers and researchers to streamline trial activation and improve enrollment in cancer studies.
• Office of the National Coordinator for Health Information Technology (ONC): Exploring ways to connect patients with clinical trials through electronic health records.
• ARPA-H: Advancing programs such as THRIVE and CATALYST to use AI and machine learning to improve trial design, predict safety, optimize dosing, and test multiple therapies simultaneously.
• HHS Office of Inspector General: Seeking public feedback on potential updates to regulations affecting incentives and participation in clinical trials.

Amid rising anemia in India, especially among pregnant women, the government has initiated the use of intravenous (IV) iron therapy to combat a condition that continues to be a significant public health challenge.

To date, four high-burden states have rolled out IV Ferric Carboxymaltose (FCM) therapy under the Anemia Mukt Bharat (AMB) initiative. Rajasthan was the first to launch the FCM Pink Drive in November 2025, followed by Andhra Pradesh (February 2026), Bihar (March 2026), and Uttar Pradesh (April 2026).

“The use of intravenous (IV) iron therapy has emerged as a scientifically sound alternative to restore iron levels and improve outcomes,” said Aradhana Patnaik, IAS, Additional Secretary and Mission Director (NHM). She added that it addresses moderate-to-severe anemia in pregnant women more effectively, particularly where oral iron is poorly tolerated or ineffective.

What Is Anemia ?

Anemia is a condition in which the number of red blood cells or their oxygen-carrying capacity is insufficient to meet the body's physiological needs.

Anemia during pregnancy is associated with postpartum hemorrhage, neural tube defects, low birth weight, premature births, stillbirths, and maternal and neonatal mortality. It can continue to affect women in the postpartum period and may worsen due to blood loss during and after delivery. This contributes to an intergenerational cycle of poor health and suboptimal growth.

According to the National Family Health Survey (NFHS-5), anemia remains a major public health issue in India, affecting:

• 52.2 per cent of pregnant women

• 60.6 per cent of lactating mothers

In an interview with HealthandMe, Prof. Dr. Sanjay Pandey, Head of the Department of Community and Family Medicine at AIIMS Patna, explained the rationale behind the therapy and its rollout in Bihar.

Why Are Women More Vulnerable to Anemia ?

Dr. Sanjay: Women are especially vulnerable to anemia because of menstrual blood loss, increased iron requirements during pregnancy, blood loss during childbirth, repeated pregnancies, poor dietary iron intake, infections, and certain genetic blood disorders.

What Is IV-FCM and How Does It Work?

Dr. Sanjay: Ferric Carboxymaltose (IV-FCM) is an injectable form of iron administered directly into the bloodstream. It is used to treat moderate-to-severe anemia when oral iron tablets are insufficient or poorly tolerated.

Unlike tablets, which depend on the gut to absorb iron slowly, a single IV-FCM infusion can deliver a full therapeutic dose in around 15 minutes, correcting hemoglobin levels within weeks.

How Is IV Iron Therapy Better Than Oral Iron?

Dr. Sanjay: One of the key advantages of FCM is that it can deliver up to 1,000 mg of iron in a single infusion lasting about 15 minutes, often resulting in a significant improvement in hemoglobin levels within two to four weeks.

The therapy reduces the need for

• multiple hospital visits,
• improves treatment compliance,
• causes fewer gastrointestinal side effects than oral iron,
• carries a lower risk of hypersensitivity reactions than older formulations such as iron dextran
• It also requires fewer infusions than iron sucrose.

When Is IV-FCM Recommended?

Dr. Sanjay: IV-FCM is recommended for:

• Pregnant Women: IV-FCM is recommended from the second trimester onwards, particularly in cases of moderate-to-severe anemia (Hb 5–9.9 g/dL). Studies indicate that FCM does not cross the placenta and does not negatively impact neonatal outcomes, including birth weight or fetal growth.

• Dose in Pregnancy: IV-FCM is given as an infusion of up to 1,000 mg in one sitting, mixed in 100 mL of normal saline over approximately 15 minutes. It should not be administered more than once a week.

How Safe Is IV Iron Therapy for Mother and Baby?

Dr. Sanjay: IV-FCM is considered safe and effective during pregnancy, with growing evidence supporting its use from the second trimester onwards.

• Maternal Outcomes: FCM corrects anemia rapidly. In the large Indian real-world PROMISE study involving 1,191 pregnant women, a single course of IV-FCM increased hemoglobin by approximately 2.8 g/dL within four weeks and by 3.6 g/dL among women with severe anemia , alongside significant improvement in iron stores.

• Neonatal Outcomes: FCM does not cross the placenta and has not been shown to adversely affect the baby. Studies report no negative impact on birth weight, five-minute Apgar scores, or fetal growth.

Are There Any Side Effects?

Dr. Sanjay: Women are typically observed for 30 minutes after infusion, and hemoglobin levels are reassessed after four weeks. IV-FCM is generally well tolerated. Mild side effects such as nausea, headache, dizziness, temporary increases in blood pressure and infusion-site reactions may occur.

How Bihar Is Expanding Access to IV-FCM Therapy

Dr. Sanjay: Bihar has procured around 2 lakh doses of IV-FCM. The rollout is expected to strengthen anemia management closer to communities through district hospitals and community health centers.

The program will improve access to advanced anemia treatment, particularly in rural areas where anemia prevalence among pregnant women exceeds 63 per cent.